Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of $0.30, $0.14 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $102.7 million versus the consensus estimate of $113.66 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.